Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Michael E. Kelly MD, PhD

Michael E. Kelly MD, PhD

Associate Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Oncology

Member of the Cancer Center


Research Experience

  • Leukemia
  • Vascular Neoplasms
  • Clinical Expertise

  • Hemangioma
  • Leukemia
  • Neoplasms, Vascular Tissue
  • Publications

  • Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. (Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, Kelly ME, Krol A, Lofgren S, Mancini AJ, Metry DW, Recht M, Silverman RA, Tom WL, Pope E) Pediatr Blood Cancer 2012 Nov;59(5):934-8 PMID 22648868
  • Endoscopic management of gastrointestinal bleeding from multifocal lymphangioendotheliomatosis with thrombocytopenia: limited efficacy and complications. (Noel RJ, Duffy KJ, Kelly ME, Tondravi N, North PE, Drolet BA) J Pediatr Gastroenterol Nutr 2012 Jun;54(6):822-4 PMID 21788915
  • Microcystic adnexal carcinoma: the first reported congenital case. (Smart DR, Taintor AR, Kelly ME, Lyon VB, Segura A, Jensen JN, Drolet BA) Pediatr Dermatol 2011 Jan-Feb;28(1):35-8 PMID 21276051
  • Kasabach-Merritt phenomenon. (Kelly M) Pediatr Clin North Am 2010 Oct;57(5):1085-9 PMID 20888459
  • Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. (Kelly ME, Juern AM, Grossman WJ, Schauer DW, Drolet BA) Arch Dermatol 2010 Jul;146(7):767-74 PMID 20479291
  • Expanding the phenotype of multifocal lymphangioendotheliomatosis with thrombocytopenia. (Maronn M, Catrine K, North P, Browning MB, Kerschner JE, Noel R, Drolet BA, Kelly M) Pediatr Blood Cancer 2009 Apr;52(4):531-4 PMID 19058203
  • Renal cell carcinoma in a patient with cystinosis and inflammatory bowel disease: a case report. (Cameron C, Greenbaum L, Sato T, Trost B, Lundeen B, Kelly ME) Pediatr Nephrol 2008 Jul;23(7):1167-70 PMID 18286306
  • Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F). (Lai JS, Cella D, Kupst MJ, Holm S, Kelly ME, Bode RK, Goldman S) J Pediatr Hematol Oncol 2007 Jul;29(7):471-9 PMID 17609625
  • Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. (Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S) Pediatr Blood Cancer 2008 Apr;50(4):822-5 PMID 17570702
  • Successful umbilical cord blood stem cell transplantation in a patient with Rothmund-Thomson syndrome and combined immunodeficiency. (Broom MA, Wang LL, Otta SK, Knutsen AP, Siegfried E, Batanian JR, Kelly ME, Shah M) Clin Genet 2006 Apr;69(4):337-43 PMID 16630167
  • Critical function of the CD40 pathway in parvovirus B19 infection revealed by a hypomorphic CD40 ligand mutation. (Blaeser F, Kelly M, Siegrist K, Storch GA, Buller RS, Whitlock J, Truong N, Chatila TA) Clin Immunol 2005 Dec;117(3):231-7 PMID 16169277
  • Posttransplantation lymphoproliferative disorder in children: clinical, histopathologic, and imaging features. (Pickhardt PJ, Siegel MJ, Hayashi RJ, Kelly M) Radiology 2000 Oct;217(1):16-25 PMID 11012419
  • High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. (Cohen AH, Sweet SC, Mendeloff E, Mallory GB Jr, Huddleston CB, Kraus M, Kelly M, Hayashi R, DeBaun MR) Am J Respir Crit Care Med 2000 Apr;161(4 Pt 1):1252-5 PMID 10764320
  • Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. (Mistry MJ, Clay MA, Kelly ME, Steiner MA, Harmony JA) Cell Immunol 1995 Jan;160(1):14-23 PMID 7842480
  • Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. (Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA) Cell Immunol 1994 Dec;159(2):124-39 PMID 7994749
  • alpha-Difluoromethylornithine induces differentiation of a human embryonal carcinoma cell line in vitro. (Uhl L, Kelly M, Schindler J) Biochem Biophys Res Commun 1986 Oct 15;140(1):66-73 PMID 3096321
  • Alterations in polyamine metabolism during embryonal carcinoma cell differentiation in vitro. (Kelly M, McCann PP, Schindler J) Dev Biol 1985 Oct;111(2):510-4 PMID 3930315
  • The response of several murine embryonal carcinoma cell lines to stimulation of differentiation by alpha-difluoromethylornithine. (Schindler J, Kelly M, McCann PP) J Cell Physiol 1985 Jan;122(1):1-6 PMID 3917438
  • Inhibition of ornithine decarboxylase induces embryonal carcinoma cell differentiation. (Schindler J, Kelly M, McCann PP) Biochem Biophys Res Commun 1983 Jul 18;114(1):410-7 PMID 6411082
  • Grants and Awards

  • COG Phase 1 PCR 2012-13 - Fixed Fee (#9208068 09/26/2012 - 07/31/2015) Sponsor: Children's Hospital of Philadelphia
  • An Open-Label Treatment Protocol For The Use Of Voraxaze As Adjunctive Treatment For Patients Experiencing Or At Risk Of Methotrexate Toxicity (PR001-CLN-pro016) (#9305859 12/02/2011 - 01/01/2013) Sponsor: CTI Clinical Trial Services, Inc.
  • Cookies For Kids' Cancer Phase I Supplemental Reimbursement (#9208856 08/01/2012 - 07/31/2015) Sponsor: Children's Hospital of Philadelphia
  • COG Non-Industry Work Order - St Baldricks (#9305979 03/01/2011 - 04/24/2015) Sponsor: Children's Hospital of Philadelphia
  • An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Leukemia (#9305145 06/15/2010 - 06/14/2015) Sponsor: Cephalon, Inc.
  • St. Baldrick's Foundation Support: ALTE11C2 Study (#9306750 10/31/2014 - 10/30/2015) Sponsor: Children's Hospital of Philadelphia
  • 100EUSA12 - An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of IV Erwinaze Following Allergy to Asparaginase, Pegaspargase or Calaspargase pegol in Children with ALL or Lymphoblastic Lymphoma (#9305917 10/16/2012 - 10/15/2015) Sponsor: EUSA Pharma
  • 2014 Children's Operational Award (#9208426 01/01/2014 - 12/31/2014) Sponsor: Children's Hospital of Wisconsin
  • Children's Oncology Group (#9301162 11/14/1997 - 06/30/2017) Sponsor: Various
  • A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD (#9305931 12/14/2012 - 02/12/2015) Sponsor: Children's Hospital of Philadelphia
  • BIQSFP-COG AALL0932 11XS197 PCR (#9208481 03/30/2012 - 06/30/2015) Sponsor: Children's Hospital of Philadelphia
  • Study: ADVL1213-Morphotek, Inc. (#9306452 03/12/2014 - 03/11/2017) Sponsor: Children's Hospital of Philadelphia
  • Pfizer Support: Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA) in Children w Relapsed Refractory Solid Tumors (#9306783 10/29/2014 - 10/28/2015) Sponsor: Children's Hospital of Philadelphia
  • Cancer Trials Support Unit (CTSU) Phase II Supplemental Payments (#9208862 01/04/2012 - 01/03/2016) Sponsor: Children's Hospital of Philadelphia
  • A Phase II Study of MLN8237 (IND#102984), a Selective Aurora A Kinase Inhibitor in Children w Recurrent/Refractory Solid Tumors & Leukemias (#9306636 09/09/2013 - 09/08/2014) Sponsor: Children's Hospital of Philadelphia
  • COG Non-Industry Work Order - CCOP (#9208104 07/24/2012 - 05/31/2015) Sponsor: Children's Hospital of Philadelphia
  • A Phase 1 Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (#9306294 11/20/2013 - 11/19/2014) Sponsor: Children's Hospital of Philadelphia
  • A Multicenter, Open-Label, Non-controlled Phase II study of Oral Nilotinib in Pediatric Patients with Newly Diagnosed Ph+ CML, CP, Ph+ CMS in CP or Ph+ ALL (#9306634 04/30/2014 - 04/29/2015) Sponsor: Children's Hospital of Philadelphia
  • Leukemia & Lymphoma Society Support: ALTE11C2 Study (#9306751 10/31/2014 - 10/30/2015) Sponsor: Children's Hospital of Philadelphia
  • Children's Oncology Group - Patient Reimbursement (#9207365 03/01/2012 - 02/28/2015) Sponsor: Children's Hospital of Philadelphia
  • The Children's Oncology Group (COG) Phase I / Pilot Consortium (#9208156 08/01/2012 - 07/31/2015) Sponsor: Children's Hospital of Philadelphia
  • Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (#9306485 03/12/2014 - 03/11/2017) Sponsor: Children's Hospital of Philadelphia
  • CA180-372 (COG-AALL1122) , A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (#9305720 05/02/2012 - 03/04/2015) Sponsor: Children's Hospital of Philadelphia
  • Children's Oncology Group Chair's Grant - Budget Based (#9208492 03/01/2014 - 02/28/2015) Sponsor: Children's Hospital of Philadelphia
  • A Phase 1 Study of Eribulin Mesylate (E7389, IND#116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lymphomas (#9306780 08/11/2014 - 08/10/2017) Sponsor: Children's Hospital of Philadelphia
  • A Phase II Study of Sunitinib in Recurrent or Progressive Brain Tumors in Pediatric and Young Adult Patients; ACNS1021 PFIZER NO. WS281593-48 (#9305961 12/14/2012 - 12/13/2015) Sponsor: Children's Hospital of Philadelphia
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluaation of Rituximab Ffficacy and Safety in High Risk Patients (#9306730 09/18/2014 - 09/17/2015) Sponsor: Children's Hospital of Philadelphia